GLP-1 users urged to preserve muscle

Weight-loss drugs are getting a new warning label in practice, even if not on the box: don’t let the scale drop faster than your strength. The concern is simple. GLP-1 drugs like semaglutide and tirzepatide help people lose a lot of weight, but some of that loss can come from lean mass, not just fat. That has pushed doctors, obesity researchers, and exercise specialists to make muscle preservation part of the treatment plan — not an afterthought. ### Why are people suddenly talking about muscle? Because the conversation around GLP-1s has matured. Early on, the headline was total pounds lost. Now the more useful question is what kind of weight people are losing. The American Diabetes Association highlighted this shift in 2025 when it spotlighted muscle preservation as a key issue in obesity treatment, noting that lean body mass can make up roughly 15% to 40% of total weight lost on GLP-1 therapies. ### Is that definitely a problem? Not in every case — and that’s the nuance. Some lean-mass loss happens with almost any meaningful weight loss, whether it comes from diet, surgery, or medication. The real worry is when weight comes off quickly, appetite drops hard, protein intake falls, and physical activity — especially resistance training — doesn’t keep up. Then the body has fewer signals telling it to hold on to muscle. Nature Reviews Endocrinology put it pretty plainly in 2025: rapid GLP-1-driven weight loss can come at the cost of skeletal muscle, which may hurt metabolic health and physical function if nobody actively manages it. ### Why does muscle matter so much? Muscle is not just gym vanity. It helps with strength, balance, mobility, glucose disposal, and resting energy use. Lose too much of it and the number on the scale may look great while the body underneath becomes less resilient. That matters even more for older adults, people already starting with low muscle mass, and anyone using these drugs for months or years. Basically, “weight loss” and “better body composition” are not the same thing. ### So what are experts telling GLP-1 users to do? Three things keep coming up: lift weights, eat enough protein, and track function instead of just body weight. Resistance training is the big one because it gives the body a reason to keep muscle during a calorie deficit. Protein matters because GLP-1 drugs often blunt appetite, which can make people unintentionally under-eat. And function matters because being able to carry groceries, climb stairs, or maintain grip and leg strength tells you more than a shrinking waistline alone. ### Is there actual research behind that advice? Yes, and it’s moving from theory into trial design. A randomized study protocol published in BMJ Open and registered on ClinicalTrials.gov is now testing exactly this question in adults starting semaglutide or tirzepatide — comparing resistance exercise, protein supplementation, both together, or neither over 6 months. That tells you where the field is headed: muscle preservation is no longer a side note. It’s becoming a formal treatment target. ### Are drug companies trying to solve this too? They are. The ADA spotlighted the BELIEVE Phase 2b trial, where bimagrumab plus semaglutide improved fat loss while helping preserve lean mass better than either drug alone. That does not mean everyone will end up on combination therapy, but it shows the industry sees “quality of weight loss” as the next battleground. ### What should someone actually take from this? The point is not that GLP-1 drugs are bad for muscle. The point is that they work best when they’re treated like part of a full program. If appetite is down and body weight is falling, the body needs a counter-signal — progressive strength training, adequate protein, and some attention to performance, not just pounds. The new message is basically this: don’t just lose weight. Keep the machinery that lets you use your body well.